Clinical Trial Detail

NCT ID NCT02147990
Title Open Label Safety and Efficacy Study of Rociletinib (CO-1686) in Patients With T790M Positive NSCLC Who Have Failed One Previous EGFR-Directed TKI
Recruitment Active, not recruiting
Gender both
Phase Phase II
Variant Requirements yes
Sponsors Clovis Oncology, Inc.
Indications

non-small cell lung carcinoma

Therapies

Rociletinib

Age Groups: adult

Additional content available in CKB BOOST